← Back to patent-cliff list
Selnoflast
Tier C — Watch / tradeSelnoflast
Inflazome
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NLRP3
Indications (approved)：Atherosclerosis, Inflammatory disease, Asthma, Parkinson's disease, Chronic obstructive pulmonary disease, Ulcerative colitis, Cryopyrin蛋白相关周期性综合征
Regional status
US
Phase II
2026-06-05
EU
Phase I
2021-11-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Selnoflast?
Approved indications include: Atherosclerosis, Inflammatory disease, Asthma, Parkinson's disease, Chronic obstructive pulmonary disease, Ulcerative colitis, Cryopyrin蛋白相关周期性综合征.
When does the Selnoflast patent expire?
No public expiry year is available for Selnoflast yet; this page updates once verified.
How do I get a quote for Selnoflast intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22